AU2006261108A1 - Method and composition to treat skin ulcers - Google Patents
Method and composition to treat skin ulcers Download PDFInfo
- Publication number
- AU2006261108A1 AU2006261108A1 AU2006261108A AU2006261108A AU2006261108A1 AU 2006261108 A1 AU2006261108 A1 AU 2006261108A1 AU 2006261108 A AU2006261108 A AU 2006261108A AU 2006261108 A AU2006261108 A AU 2006261108A AU 2006261108 A1 AU2006261108 A1 AU 2006261108A1
- Authority
- AU
- Australia
- Prior art keywords
- proanthocyanidins
- composition
- patient
- days
- venous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title claims description 22
- 206010040943 Skin Ulcer Diseases 0.000 title description 12
- 231100000019 skin ulcer Toxicity 0.000 title description 3
- 229920002770 condensed tannin Polymers 0.000 claims description 81
- 208000025865 Ulcer Diseases 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 35
- 231100000397 ulcer Toxicity 0.000 claims description 35
- 230000000699 topical effect Effects 0.000 claims description 12
- 241001236212 Pinus pinaster Species 0.000 claims description 9
- 235000005105 Pinus pinaster Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 235000010204 pine bark Nutrition 0.000 claims description 6
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003357 wound healing promoting agent Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- -1 drinks Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 235000018192 pine bark supplement Nutrition 0.000 description 27
- 229940106796 pycnogenol Drugs 0.000 description 27
- 230000035876 healing Effects 0.000 description 18
- 206010052428 Wound Diseases 0.000 description 11
- 201000002816 chronic venous insufficiency Diseases 0.000 description 11
- 201000002282 venous insufficiency Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 9
- 238000007906 compression Methods 0.000 description 9
- 230000006835 compression Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000036269 ulceration Effects 0.000 description 9
- 230000004087 circulation Effects 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229920002414 procyanidin Polymers 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 229920001991 Proanthocyanidin Polymers 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 208000000558 Varicose Ulcer Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 4
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 4
- 244000105624 Arachis hypogaea Species 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 description 4
- 240000006365 Vitis vinifera Species 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 229950001002 cianidanol Drugs 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000020232 peanut Nutrition 0.000 description 4
- 229940106587 pine bark extract Drugs 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 3
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 208000005230 Leg Ulcer Diseases 0.000 description 3
- 244000070406 Malus silvestris Species 0.000 description 3
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 150000004775 coumarins Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 3
- 235000012734 epicatechin Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000007632 sclerotherapy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000037997 venous disease Diseases 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 240000004584 Tamarindus indica Species 0.000 description 2
- 235000004298 Tamarindus indica Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 241001106462 Ulmus Species 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 240000001717 Vaccinium macrocarpon Species 0.000 description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000004634 cranberry Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 235000016795 Cola Nutrition 0.000 description 1
- 241001634499 Cola Species 0.000 description 1
- 235000011824 Cola pachycarpa Nutrition 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229930182448 Prodelphinidin Natural products 0.000 description 1
- 229920000124 Prodelphinidin Polymers 0.000 description 1
- 229920002783 Propelargonidin Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002857 effect on ulcer Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/166,510 | 2005-06-23 | ||
| US11/166,510 US20060293258A1 (en) | 2005-06-23 | 2005-06-23 | Method and composition to treat skin ulcers |
| PCT/EP2006/006048 WO2006136428A2 (en) | 2005-06-23 | 2006-06-23 | Method and composition to treat skin ulcers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006261108A1 true AU2006261108A1 (en) | 2006-12-28 |
Family
ID=37568333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006261108A Abandoned AU2006261108A1 (en) | 2005-06-23 | 2006-06-23 | Method and composition to treat skin ulcers |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060293258A1 (enExample) |
| EP (1) | EP1896010A2 (enExample) |
| JP (1) | JP2008543902A (enExample) |
| AU (1) | AU2006261108A1 (enExample) |
| CA (1) | CA2612750A1 (enExample) |
| WO (1) | WO2006136428A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2657915A1 (en) * | 2006-07-21 | 2008-01-24 | Mars, Incorporated | Improvement of arginase levels/activity |
| RU2012126140A (ru) * | 2009-11-25 | 2013-12-27 | Нестек С.А. | Питательные композиции, включающие высокобелковый компонент и экзогенные нуклеотиды |
| CA2880439C (en) * | 2012-08-07 | 2018-08-21 | Indus Biotech Private Limited | Use of procyanidin compositions in the treatment of diabetic foot ulcers, pressure ulcers and venous leg ulcers |
| JPWO2014104064A1 (ja) * | 2012-12-26 | 2017-01-12 | 株式会社エーゼット | 創傷治癒促進剤 |
| US10398664B2 (en) | 2013-05-01 | 2019-09-03 | Lanny Leo Johnson | Methods of diagnosing and treating infected implants |
| US10016380B2 (en) | 2013-05-01 | 2018-07-10 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
| WO2014179318A2 (en) * | 2013-05-01 | 2014-11-06 | Johnson Lanny Leo | Antimicrobials and methods of use thereof for wound healing |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8518289D0 (en) * | 1985-07-19 | 1985-08-29 | Inverni Della Beffa Spa | Obtaining proanthocyanidine a2 |
| JPS6377390A (ja) * | 1986-09-20 | 1988-04-07 | Sanyo Electric Co Ltd | キヤプスタンモ−タサ−ボ回路 |
| IT1270999B (it) * | 1994-07-26 | 1997-05-26 | Indena Spa | Formulazioni a base di cumarine e loro uso in campo farmaceutico e cosmetico |
| US5470874A (en) * | 1994-10-14 | 1995-11-28 | Lerner; Sheldon | Ascorbic acid and proanthocyanidine composition for topical application to human skin |
| US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
| JP2001511153A (ja) * | 1997-02-04 | 2001-08-07 | ブイ． コスバブ，ジョン | 血管変性性疾患の予防および処置のための組成物および方法 |
| KR100509119B1 (ko) * | 1999-07-16 | 2005-08-18 | 주식회사 엘지생활건강 | 프로시아니딘 올리고머를 유효성분으로 하는 약제 |
| BR9902972B1 (pt) * | 1999-07-16 | 2012-02-22 | composição bifásica de uso cosmético ou farmacêutico. | |
| JP2001122791A (ja) * | 1999-10-20 | 2001-05-08 | Boehringer Ingelheim Internatl Gmbh | 下肢の慢性静脈不全の軽減および予防のための赤色ブドウ樹葉の水性抽出物よりなる食事補強剤 |
| JP2005047818A (ja) * | 2002-07-29 | 2005-02-24 | Toyo Shinyaku:Kk | 健康食品および健康飲料 |
| JP2005047839A (ja) * | 2003-07-31 | 2005-02-24 | Toyo Shinyaku:Kk | プロアントシアニジン含有組成物 |
-
2005
- 2005-06-23 US US11/166,510 patent/US20060293258A1/en not_active Abandoned
-
2006
- 2006-06-23 CA CA002612750A patent/CA2612750A1/en not_active Abandoned
- 2006-06-23 EP EP06762149A patent/EP1896010A2/en not_active Withdrawn
- 2006-06-23 AU AU2006261108A patent/AU2006261108A1/en not_active Abandoned
- 2006-06-23 JP JP2008517423A patent/JP2008543902A/ja active Pending
- 2006-06-23 WO PCT/EP2006/006048 patent/WO2006136428A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2612750A1 (en) | 2006-12-28 |
| US20060293258A1 (en) | 2006-12-28 |
| EP1896010A2 (en) | 2008-03-12 |
| WO2006136428A3 (en) | 2007-04-12 |
| JP2008543902A (ja) | 2008-12-04 |
| WO2006136428A2 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sieniawska | Activities of tannins–from in vitro studies to clinical trials | |
| Khorasani et al. | Aloe versus silver sulfadiazine creams for second-degree burns: a randomized controlled study | |
| Belcaro et al. | Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol® | |
| CN108136027A (zh) | 用于活性成分的基于凡士林的递送系统 | |
| Smith | Drug treatment of varicose veins, venous edema, and ulcers | |
| IL225939A (en) | Preparations for the treatment of peripheral ulcer from a variety of sources | |
| US20060293258A1 (en) | Method and composition to treat skin ulcers | |
| KR20130120375A (ko) | 피부 궤양을 치료 및/또는 예방하기 위한 성분의 키트 | |
| AU2012307406B2 (en) | Compositions for the treatment of peripheral ulcers of various origins | |
| US20250090598A1 (en) | Systems and methods for thrombosis prevention | |
| ES2335729B1 (es) | Composicion cosmetica para pieles sensibles. | |
| KR20140104823A (ko) | 당뇨병성 창상의 예방 또는 치료용 약학 조성물 | |
| US9421235B2 (en) | Medicine containing extracts of Ficus microcarpa for healing wounds of a diabetic patient | |
| RU2325175C2 (ru) | Мазь для лечения ожогов, кожных заболеваний и заживления ран | |
| RU2416425C1 (ru) | Масло противопролежневое | |
| RS55672B1 (sr) | Supstance oleuropeina za lečenje rana i čireva kod starijih ljudi i/ili dijabetičara | |
| Abascal et al. | Botanicals for chronic venous insufficiency | |
| Nair et al. | Achieving oral health the natural way: Pomegranate | |
| Gardner | L-Mesitran® | |
| Daley | Chronic venous insufficiency | |
| KR20140104932A (ko) | 당뇨병성 창상의 예방 또는 치료용 약학 조성물 | |
| Ambizas et al. | Dermatologic Conditions | |
| CN111419952A (zh) | 一种具有止血止痛作用的中药组合物及其制备方法和应用 | |
| Shojaii | 22 Myrtus communis L. | |
| Belcaro et al. | Treatment of chronic venous insufficiency and prevention of economy class syndrome. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |